Synthetic oligodeoxynucleotides complementary to the breakpoint junction of bcr-abl transcripts selectively inhibit the proliferation of Philadelphia'-positive leukemic cells, but residual leukemic cells persist in antisense oligodeoxynucleotidestreated cultures. Cyclophosphamide derivatives such as mafosfamide and 4-hydroperoxycyclophosphamide are used at high doses for purging of Philadelphia' leukemic cells from marrows but such treatment can be associated with delayed engraftment and prolonged cytopenias. To develop a more effective procedure that might optimize the killing of leukemia cells and the sparing of normal hematopoietic progenitor cells, a 1:1 mixture of Philadelphia' leukemic cells and normal bone marrow cells was exposed to a combination of a low dose of mafosfamide and bcr-abl antisense oligodeoxynucleotides and assayed for growth ability in clonogenic assays and in immunodeficient mice. Bcr-abl transcripts were not detected in residual colonies, and cytogenetic analysis of individual colonies revealed a normal karyotype. Normal but not leukemic hematopoietic colonies of human origin were also detected in marrows of immunodeficient mice 1 mo after injection of the treated cells. Our results indicate that a combination of a conventional chemotherapeutic agent and a tumor-specific antisense oligodeoxynucleotide is highly effective in killing leukemic cells and in sparing a much higher number of normal progenitor cells as compared with high-dose mafosfamide treatment. This offers the prospect of a novel and more selective ex vivo treatment of chronic myelogenous leukemia. (J. Clin. Invest. 1993.92:194-202.)
crease the probability of long-term remission or even cure of these patients ( 1 ) . Allogeneic or syngeneic BMT has improved the clinical prognosis, but this therapy is applicable only to a minority of patients because histocompatible marrow donors are scarce. In the absence of appropriate donors, autologous BMT may be performed, although the results ofsuch treatment are usually worse compared with allogeneic marrow transplantation (2, 3) , owing to residual clonogenic leukemia cells within the autograft and lack of graft-vs.-leukemia effect (4) . However, a beneficial effect of autologous BMT in CML patients has been reported, but remission (when achieved) was usually brief (5, 6) . Thus, improvement in CML treatment depends on the establishment ofa better method ofex vivo and in vivo treatment of leukemic cells.
The presence ofthe bcr-abl break point in CML cells (7, 8) and the demonstration that bcr-abl transcripts play an essential role in the induction and maintenance of the leukemic phenotype (9, 10) offers the unique opportunity to utilize these antisense oligodeoxynucleotides, alone or in combination with conventional chemotherapeutic agents, as tumor-specific in vitro purging agents. Among the candidate chemotherapeutic agents mafosfamide has been used with promising results as a purging agent in acute leukemia in a nonrandomized trial ( 11 ) . A theoretical objection to the purging of bone marrow cells (BMC) from CML patients rests in the observation that the vast majority of hematopoietic cells in bone marrow or peripheral blood of CML patients are neoplastic so that repopulation with normal hematopoietic cells upon reintroduction of purged cells is questionable. However, nonclonal, presumably nonneoplastic hematopoiesis can be temporarily restored in vivo after chemotherapy ( 12), interferon treatment ( 13) , or autologous BMT using unpurged or purged autografts (14) (15) (16) . In in vitro longterm bone marrow cultures, the dominant Philadelphia ' (Ph' )-positive cell population disappeared, and karyotypically normal progenitors remained detectable for a long period of time ( 17). Accordingly, the development of an effective strategy for the ex vivo treatment ofCML cells might have therapeutic utility.
Using clonogenic assays, we have examined the in vitro sensitivity ofCML-blast crisis (BC), and normal BMC to highdose mafosfamide (ASTA Z 7654), or to a combination of low-dose mafosfamide and bcr-abl antisense oligodeoxynucleotides. This combination purge is highly effective in eliminating Ph' leukemic cells, and in sparing a larger number of normal hematopoietic progenitors as compared with (19) and is characterized by the presence of the b2/a2 break point and common acute lymphoblastic leukemia antigen (CALLA), and the absence of CD45 antigen (19, Oligodeoxynucleotides. These were synthesized on a DNA synthesizer (model 380B, Applied Biosystems, Inc., Foster City, CA) by means of fl-cyanoethylphosphorymidite chemistry. The sequences of b2/a2 and b3/a2 antisense oligodeoxynucleotides, the 5' primer ofbcr exon 2, the 3' primer of abl exon 2, and the abl probe recognizing the amplified 257-bp bcr-abl transcript have been described (10) . The sequences of 5' and 3' primers of human a-satellite DNA are as described (21) and the 32-base probe corresponds to nucleotides 77-108 of the published sequence of human a-satellite (22) . The (B2-microglobulin ((f2) 5' and 3' primers correspond to nucleotides 280-301 and 510-531, respectively, and the 50-base probe corresponds to nucleotides 351-400 (23) . ,B-Actin oligomers were made based on the published sequence of mouse fl-actin (24) . Primers synthesized for murine f3-actin cross-reacted with human f,-actin (not shown), and the probe corresponds to nucleotides 258-296 (25 Colony assays. CFU-GM colonies were grown and counted as described ( 18). 5 X I04 ofA-T-MNC or CML cells were plated in HCC-4230 medium (Terry Fox Laboratories, Vancouver, BC) supplemented with IL-3 (20 U/ml), GM-CSF (5 ng/ml), and 0.125 mM L-glutamine in duplicate 35-mm Petri dishes (Nunc Inc., Naperville, IL) at 1 ml per dish. Growth of human colonies derived from 105 mouse marrow cells plate was, in addition, supported with recombinant human SCF ( 100 ng/ml) and recombinant human erythropoietin (2 U/ml). Colonies and clusters were scored after 9-12 d ofculture in a humidified 5% CO2 incubator.
Reverse transcriptase-polymerase chain reaction (RT-PCR). Cells were collected separately from each experimental group, centrifuged on Histopaque-1077 density gradient, and washed before total RNA extraction in the presence of 20 Ag of Escherichia coli ribosomal RNA as described (26). RNA from each group was divided into two aliquots. One sample was reverse-transcribed using 400 U of Moloney murine leukemia virus RT (BRL, Gaithersburg, MD) and 0.1 tLg of3' primer of abl exon 2 for I h at 370C. The second sample was reverse-transcribed using the 2-microglobulin 3' primer. The resulting cDNA fragments were amplified with 5 U of Thermuts aquaticuts (Taq) polymerase (Perkin Elmer Cetus, Norwalk, CT) in the presence of the 5' primer of bcr exon 3 or #2-microglobulin 5' primer, generating a 257-bp fragment corresponding to the bcr/abl break-point region, and a 252-bp fragment of,2-microglobulin during 56 cycles ofPCR (27) . Reaction products were electrophoresed in 2% agarose gel, transferred to Zeta-probe blotting membranes (Bio-Rad Laboratories, Richmond, CA) and hybridized overnight at 50°C using the abl exon 2 or 32-microglobulin probes end-labeled with [ Single-colony PCR analysis. Single colonies were picked separately and divided into two portions; RNA was prepared as described ( 18) from one portion, and DNA was extracted by repeated freezing and thawing from the other. RNA was reverse-transcribed using the abl exon 2 or ,B-actin 3' primers. The resulting cDNA was amplified using the bcr exon 2 and the ,B-actin 5' primers, respectively, and Taq polymerase as described above. DNA was amplified with human a-satellite 3' and 5' primers and Taq polymerase, and PCR amplification products were electrophoresed, transferred, and hybridized as described for RT-PCR.
Immunofluorescence studies. For flow cytometry analysis, singlecell suspensions were prepared from bone marrow of mice injected with human cells. Cells (105) were stained with FITC-conjugated mouse anti-HLe-l (anti-CD45) or anti-CALLA (anti-CD10) monoclonal antibody (Becton-Dickinson Immunocytometry Systems, San Jose, CA), washed, and analyzed by flow cytometry using the Epics Profile Analyzer (Coulter Corp., Hialeah, FL). For each cell type, two negative controls were used: the same cell population stained with FITC-conjugated anti-human CD3 monoclonal antibody, and BMC stained with FITC-conjugated anti-HLe-I or anti-CALLA from noninjected mice. Human peripheral blood mononuclear cells (99% positivity) and BV173 cells (95% positivity) served as positive control for anti-CD45 and anti-CD-10 monoclonal antibodies, respectively. The level ofsensitivity for each antibody was -10-2 . Negative and positive controls were utilized in each set of experiments.
Cytogenetic analysis ofsingle hematopoietic colonies. A 1:1 mix of normal marrow progenitors and leukemic cells was cultured in methylcellulose in the presence of bcr-abl antisense oligodeoxynucleotides, alone or in combination with mafosfamide. After 7-9 d, plates were exposed to a colcemid solution (0.3 ,g/ml) for 1 h. Single colonies were plucked from the methylcellulose, diluted with physiological saline, and centrifuged to remove residual methylcellulose. After 25 min of hypotonic treatment in 0.075 M KCl, cells were fixed by washing several times with methanol/glacial acetic acid (3:1 ). Slides were airdried and G-banded as described (29).
Results
In vitro sensitivity ofCML and normal marrow cells to mafosfamide. The sensitivity of CML-BC cells from 11 patients, and normal bone marrow hematopoietic progenitor cells from 8 healthy volunteers to mafosfamide was examined. Leukemic cells were more sensitive than normal hematopoietic cells to mafosfamide at concentrations of 25, 50, and 100 ,jg/ml ( Fig.   1 ). At the highest concentration of mafosfamide (100 ,Rg/ml), formation of colonies derived from CML-BC cells was completely inhibited in samples from 9 of 11 patients and almost completely in two other cases (-99.8% inhibition). At the same time, 3.15% (0.6-10.3%) of normal hematopoietic colonies were spared in 8 of8 samples from healthy volunteers (Fig.   1 ). The CD34' subpopulation of CML cells was also more sensitive than that ofnormal hematopoietic progenitors to mafosfamide (not shown detected after treatment with mafosfamide at 100 gg/ml, and the bcr-abl transcript was barely detectable after exposure to mafosfamide at 50 ,tg/ml (Fig. 2, bottom ,gg/ml) was combined with the b2/a2 antisense oligomer (80 + 40 + 40 ,g/ml) (Fig. 3, top) . However, a bcr-abl transcript was clearly present in colonies derived from cells treated with mafosfamide or with the antisense oligomer alone, but was not detectable after exposure to a combination of the two reagents suggesting that mafosfamide and b2/a2 antisense oligodeoxynucleotides have a synergistic effect against leukemic cells (Fig.  3, bottom) . In contrast, control f32-microglobulin mRNA, was clearly detectable in each sample (Fig. 3, bottom (Fig. 4, top) , and then total RNA was isolated from the cells. A bcr-abl transcript was clearly present in untreated cells and in cells treated with mafosfamide or with the antisense oligomer alone, but, in all three cases, was not detectable after exposure to a combination ofmafosfamide and bcr/abl antisense oligodeoxynucleotides. (Fig. 4, bottom) . In contrast, control 32-microglobulin mRNA, was clearly detectable in each sample. Fig. 4 and not leukemic because ofthe lack ofbcr/abl mRNA expression (Fig. 5 A) (Table III) . Under conditions that favor the growth of human hematopoietic cells numerous colonies were grown from bone marrow of mice injected with nontreated cells, whereas only few colonies grew after injection of purged cells (Table III) . All colonies (five colonies tested per mouse) contained human-specific a-satellite DNA sequences (Fig. 5 B) . Bcr/abl mRNA was only detected in four colonies which arose from bone marrow of the mouse injected with nontreated cells (five colonies tested per mouse) (Fig. 5 B) . The analysis of single colonies from the second group ofmice gave similar results. As expected, bcr/abl expression was detected in marrow cells of mice injected with untreated cells but not after in vitro treatment with bcr/abl JRGED A bcr-abl (Table IV) . The human origin of most of these colonies (5/6) was confirmed by detection of human a-satellite DNA sequence in PCR reaction products obtained from single colonies (Fig. 6) Mafosfamide, a cyclophosphamide derivative, is utilized to purge acute myeloid leukemia cells from autologous bone marrow grafts. A decreased probability of relapse is associated with the use of such drugs at a concentration sparing as few as 5% CFU-GM ( 11 ). Lowest relapse rates appear to be achieved using a drug concentration that spares < 1% ofCFU-GM (35) . For this reason, effective purging is often accompanied by delayed engraftment and persistent thrombocytopenia (36) . In light of conflicting observations on the efficacy of cyclophosphamide derivatives for bone marrow purging in CML patients ( 15, 37 ), we utilized colony formation assays ( 38 ) and the PCR technique (39) to determine whether Ph' leukemic cells are killed while normal progenitor cells are spared.
Our data from colony-forming assays (primary and secondary) and RT-PCR detection ofbcr-abl transcripts indicate that the colonies arising from mafosfamide (100 Ag/ml) purged bone marrow were nonneoplastic, and that the number of leukemic cells was diminished below the level ofdetection. In light of the unaltered expression of P210 bcr/abl tyrosine kinase in the presence ofcytotoxic agents that inhibit cell growth (40) , it was likely that the disappearance of the bcr/abl signal after mafosfamide treatment reflects the elimination of leukemic cells rather than the effect of the drug on bcr-abl gene expression. Although the findings reported here cannot be extrapolated to actual transplants, they nevertheless suggest that mafosfamide might be useful in some cases for purging ofcontaminating CML cells from autologous bone marrow, consistent with previous observations of other investigators (41, 42) . However, the combination of different purging techniques might be more efficient in the elimination ofleukemic cells and less toxic for normal hematopoietic stem cells.
We have recently described the selective elimination of CML-BC cells from the mixture of CML patients cells and normal BMC using antisense oligodeoxynucleotides targeted against the bcr/abl transcript ( 10) , but the procedure did not eliminate all leukemic cells. In an effort to improve the efficiency ofCML treatment, we tested the combination ofmafosfamide and bcr/abl antisense oligodeoxynucleotides at concentrations which, when used separately, did not eliminate totally the leukemic cells but spared 47% and 85% of normal hematopoietic clonogenic cells, respectively. In combination, mafosfamide and antisense oligodeoxynucleotides caused complete disappearance of the bcr/abl transcripts which suggests a very efficient elimination of detectable leukemic cells from bone marrow. Cytogenetic analysis of the cells that grew after purging revealed no Ph '-positive metaphases, which excludes the possibility of growth of "silent" leukemic cells that possess the Ph' chromosome but do not express bcr/ abl transcripts (43) , and confirms the efficacy of this treatment procedure. The in vitro results were confirmed in vivo when human BMC mixed with BV173 leukemic cells or CML-BC primary cells were treated with mafosfamide and bcr/abl antisense oligodeoxynucleotides before injection into immunodeficient SCID mice (44) subsequently supported with recombinant human hematopoietic growth factors. Normal human hematopoiesis after implantation of purged bone marrow, and primarily leukemic hematopoiesis after injection of nonpurged bone marrow were detected in bone marrow of the mice. In addition, the in vitro results (clonogenic assays) and the in vivo data (detection of human hematopoiesis in BNX mice) provide strong evidence that purging with mafosfamide plus antisense oligodeoxynucleotides spares a higher number of normal hematopoietic progenitors compared with purging with high concentrations of mafosfamide alone.
Another described procedure ofbone marrow purging from CML cells is that based on the differential sensitivity of normal and Ph '-positive hematopoietic cells to in vitro culture conditions ( 16). However, the effectiveness of this strategy is still questionable because the Ph '-positive clonogenic progenitors usually disappear within 4-6 wk of long-term cultures ( 16) , and there is variation among patients in the number ofPh '-negative cells with repopulating potential after in vitro culture (34) . A combination of mafosfamide treatment followed by in vitro culture purging and bcr-abl antisense oligodeoxynucleotide treatment might prove to be more therapeutically useful in some patients.
In summary, these data suggest that in our experimental model the combination oflow-dose mafosfamide, with bcr/abl antisense oligodeoxynucleotides offers an efficient approach to eliminate CML-BC cells from BMC while significantly improving the sparing of normal hematopoietic stem cells, as compared with that seen using mafosfamide. Preliminary evidence that antisense oligodeoxynucleotides (bcr-abl or c-myb) in combination with other chemotherapeutic agents (adriamycin, etoposide, or cis-platinum) enhance the elimination ofhematopoietic and nonhematopoietic neoplastic cells suggests the possibility of using this therapeutic strategy in the treatment of human malignancies.
